Altogether, these results support our initial computationally-driven hypothesis and suggest that BET inhibition demonstrates therapeutic potential for NASH and other fibrotic diseases (Fig. 7). The gene discussed is DNER; the disease is metabolic dysfunction-associated steatohepatitis.